.Attributes Medicine, Released online: 16 September 2024 doi:10.1038/ s41591-024-03244-8In the empirical SCRUM-Japan GOZILA research study, after an average consequence of 11 months, patients along with metastatic intestinal cysts who obtained biomarker-matched therapies based upon spreading growth DNA profiling showed a greater medical perk than those getting unequaled treatment.